antibody microarray analysis of directly labelled proteomes
In recent years, the antibody microarray technology has made significant progress, going from proof-of-concept designs to established high-performing technology platforms capable of targeting non-fractionated complex proteomes. In these cross-disciplinary efforts, a particular focus has lately been placed on two key technological issues: the sample and data handling. To this end, robust protocols
